Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 11045 results:
Συντάκτης Τίτλος [ Τύπος(Asc)] Έτος
Journal Article
Anastasilakis, A. D., Polyzos S. A., Makras P., Gkiomisi A., Sakellariou G., Savvidis M., et al. (2015).  Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment.. Expert Opin Ther Targets. 19(3), 299-306.
Anastasilakis, A. D., Polyzos S. A., Yavropoulou M. P., Ntenti C., Mandanas S., & Makras P. (2021).  Circulating sclerostin levels during denosumab discontinuation and the subsequent early or late zoledronate infusion.. Endocrine.
Polyzos, S. A., Anastasilakis A. D., Kountouras J., Makras P., Papatheodorou A., Kokkoris P., et al. (2016).  Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease.. J Bone Miner Metab. 34(4), 447-56.
Koiou, E., Tziomalos K., Katsikis I., Kalaitzakis E., Kandaraki E. A., Tsourdi E. A., et al. (2011).  Circulating platelet-derived microparticles are elevated in women with polycystic ovary syndrome diagnosed with the 1990 criteria and correlate with serum testosterone levels.. Eur J Endocrinol. 165(1), 63-8.
Sakellariou, G. T., Anastasilakis A. D., Bisbinas I., Oikonomou D., Gerou S., Polyzos S. A., et al. (2015).  Circulating periostin levels in patients with AS: association with clinical and radiographic variables, inflammatory markers and molecules involved in bone formation.. Rheumatology (Oxford). 54(5), 908-14.
Anastasilakis, A. D., Polyzos S. A., Makras P., Savvides M., Sakellariou G. T., Gkiomisi A., et al. (2014).  Circulating periostin levels do not differ between postmenopausal women with normal and low bone mass and are not affected by zoledronic acid treatment.. Horm Metab Res. 46(2), 145-9.
Anastasilakis, A. D., Polyzos S. A., Makras P., Rauner M., Sonnleitner L., Hawa G., et al. (2019).  Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone mass.. J Musculoskelet Neuronal Interact. 19(3), 253-257.
Yavropoulou, M. P., Kolynou A., Makras P., Pikilidou M., Nanoudis S., Skoura L., et al. (2021).  Circulating microRNAs Related to Bone Metabolism in HIV-Associated Bone Loss.. Biomedicines. 9(4), 
Geropoulos, G., Psarras K., Papaioannou M., Giannis D., Meitanidou M., Kapriniotis K., et al. (2022).  Circulating microRNAs and Clinicopathological Findings of Papillary Thyroid Cancer: A Systematic Review.. In Vivo. 36(4), 1551-1569.
Makri, E. S., Evripidou K., & Polyzos S. A. (2024).  Circulating leptin in patients with nonalcoholic fatty liver disease-related liver fibrosis: a systematic review and a meta-analysis.. J Gastroenterol Hepatol.
Polyzos, S. A., Aronis K. N., Kountouras J., Raptis D. D., Vasiloglou M. F., & Mantzoros C. S. (2016).  Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis.. Diabetologia. 59(1), 30-43.
Anastasilakis, A. D., Koulaxis D., Kefala N., Polyzos S. A., Upadhyay J., Pagkalidou E., et al. (2017).  Circulating irisin levels are lower in patients with either stable coronary artery disease (CAD) or myocardial infarction (MI) versus healthy controls, whereas follistatin and activin A levels are higher and can discriminate MI from CAD. Metabolism. 73, 1-8.
Aronis, K. N., Moreno M., Polyzos S. A., Moreno-Navarrete J. M., Ricart W., Delgado E., et al. (2015).  Circulating irisin levels and coronary heart disease: association with future acute coronary syndrome and major adverse cardiovascular events.. Int J Obes (Lond). 39(1), 156-61.
Anastasilakis, A. D., Polyzos S. A., Makras P., Gkiomisi A., Bisbinas I., Katsarou A., et al. (2014).  Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months.. Osteoporos Int. 25(5), 1633-42.
Anastasilakis, A. D., Polyzos S. A., Saridakis Z. G., Kynigopoulos G., Skouvaklidou E. C., Molyvas D., et al. (2014).  Circulating irisin in healthy, young individuals: day-night rhythm, effects of food intake and exercise, and associations with gender, physical activity, diet, and body composition.. J Clin Endocrinol Metab. 99(9), 3247-55.
Polyzos, S. A., Kountouras J., & Tsoukas M. A. (2015).  Circulating homocysteine in nonalcoholic fatty liver disease.. Eur J Intern Med. 26(2), 152-3.
Anastasilakis, A. D., Polyzos S. A., Skouvaklidou E. C., Kynigopoulos G., Saridakis Z. G., Apostolou A., et al. (2016).  Circulating follistatin displays a day-night rhythm and is associated with muscle mass and circulating leptin levels in healthy, young humans.. Metabolism. 65(10), 1459-65.
Dalamaga, M., Polyzos S. A., Karmaniolas K., Chamberland J., Lekka A., Migdalis I., et al. (2014).  Circulating fetuin-A in patients with pancreatic cancer: a hospital-based case-control study.. Biomarkers. 19(8), 660-6.
Makri, E., Orfanidou M., Makri E. S., Goulas A., Terpos E., & Polyzos S. A. (2024).  Circulating Ferritin in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis.. J Clin Exp Hepatol. 14(3), 101353.
Provatopoulou, S., Kalavrizioti D., Stangou M., Kouri M-N., Kalliakmani P., Papasotiriou M., et al. (2019).  Circulating anti-phospholipase A2 receptor antibodies as a diagnostic and prognostic marker in Greek patients with idiopathic membranous nephropathy - a retrospective cohort study.. Rom J Intern Med. 57(2), 141-150.
Patsatsi, A., Kyriakou A., Mantas A., Vavilis D., Patsialas C., & Sotiriadis D. (2014).  Circulating anti-BP180 NC16a and anti-BP230 autoantibodies in patients with genital lichen sclerosus do not correlate with disease activity and pruritus.. Acta Derm Venereol. 94(6), 711-2.
Vasiliadis, A. V., Zafeiridis A., Dipla K., Galanis N., Chatzidimitriou D., Kyparos A., et al. (2014).  Circulating angiogenic biomolecules at rest and in response to upper-limb exercise in individuals with spinal cord injury.. J Spinal Cord Med. 37(2), 226-32.
Savvidou, S., Karatzidou K., Tsakiri K., Gagalis A., Hytiroglou P., & Goulis J. (2016).  Circulating adiponectin levels in type 2 diabetes mellitus patients with or without non-alcoholic fatty liver disease: Results of a small, open-label, randomized controlled intervention trial in a subgroup receiving short-term exenatide.. Diabetes Res Clin Pract. 113, 125-34.
Tontikidou, C., Makri E. S., Evripidou K., Goulis D. G., Goulas A., & Polyzos S. A. (2022).  Circulating adiponectin in patients with nonalcoholic fatty liver disease-related liver fibrosis: A systematic review and a meta-analysis.. J Gastroenterol Hepatol.
Anastasilakis, A. D., Polyzos S. A., Makras P., Gkiomisi A., Savvides M., Papatheodorou A., et al. (2013).  Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment.. Osteoporos Int. 24(7), 2127-32.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.